Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tradipitant: First Approval.

Drugs·2026

Same author

Depemokimab: First Approval.

Drugs·2026

Same author

Sibeprenlimab: First Approval.

Drugs·2026

Same author

Zongertinib: First Approval.

Drugs·2026

Same author

Rilzabrutinib: First Approval.

Drugs·2025

Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025

Same journal

Advances in Gene and Cellular Therapy in Friedreich Ataxia.

Molecular diagnosis & therapy·2026

Same journal

Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer.

Molecular diagnosis & therapy·2026

Same journal

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026

Same journal

Genetics of Cerebrotendinous Xanthomatosis.

Molecular diagnosis & therapy·2026

Same journal

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026

Same journal

LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.

Molecular diagnosis & therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 30, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Obecabtagene Autoleucel: First Approval.

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular Diagnosis & Therapy

|January 31, 2025

Summary

This summary is machine-generated.

Obecabtagene autoleucel, a novel CD19-directed immunotherapy, has gained approval for relapsed or refractory B-cell acute lymphoblastic leukemia. This CAR T therapy offers a unique fast off-rate binder for CD19, simplifying patient monitoring.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Related Experiment Videos

Last Updated: May 30, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

Area of Science:

Immunotherapy
Hematologic Oncology
Cellular Therapy

Background:

Obecabtagene autoleucel (AUCATZYL®) is an innovative CD19-directed genetically modified autologous T cell immunotherapy.
It is developed for hematological cancers and systemic lupus erythematosus.

Purpose of the Study:

To summarize the development milestones of obecabtagene autoleucel.
To highlight its first approval for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Main Methods:

The development pathway leading to regulatory approval.
Evaluation of clinical trial data, including the FELIX phase I/II trial.

Main Results:

Obecabtagene autoleucel demonstrated positive results in the FELIX trial for adults with relapsed or refractory B-cell ALL.
It is the first chimeric antigen receptor T (CAR T) therapy without mandatory Risk Evaluation Mitigation Strategy monitoring.

Conclusions:

Obecabtagene autoleucel represents a significant advancement in CAR T therapy for B-cell ALL.
Its unique properties, including a fast off-rate binder and no mandatory monitoring, position it as a promising treatment option.